Astegolimab
Based on 3 publication(s) in Google Scholar
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.00%
- CAS No.: 2173054-79-8
- Masse moléculaire:144.98 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Astegolimab
More
Customer Validation & Images
-
ELISA
-
WB
Activité biologique
Human IgG2 kappa
Human
|
ST2 |
Astegolimab could block the effect of CM-induced neutrophil extracellular trap (NET) formation in HL-60 cells[2].
Astegolimab (10 μM) blocks the effect of exogenous IL33 on cardiomyocyte (AC16) senescence[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AC16 cells treated with IL33
-
Concentration:10 μM
-
Incubation Time:
-
Result:Reduced p53 expression.
Mitigated IL33-upregulated SASP factors such as IL1α, IL6 and MCP1.
Mitigated IL33-increased p-p65/p65 ratio.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Immobilized ST2/IL1RL1 Protein, Human can bind Astegolimab. The EC50 for this effect is 28.29 ng/mL. -
Loaded ST2/IL1RL1 Protein, Human (310a.a, HEK293, His, HY-P70615) on AHC2 biosensor, can bind Astegolimab with an affinity constant of 2.022E-10 M as determined in BLI assay.
Chemical Information
-
CAS No. 2173054-79-8
-
Appearance Liquid
-
Masse moléculaire 144.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Astegolimab]
-
Synonyms
MSTT 1041A; RG 6149
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. [Abstract]2026 Jun 8;44(6):1179-1200.e14. PMID: 41997138 -
Cell Oncol (Dordr)
Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. [Abstract]2025 Apr;48(2):487-504. PMID: 39585643
Astegolimab purchased from MedChemExpress. Usage Cited in: Cell Oncol (Dordr). 2025 Apr;48(2):487-504. [Abstract]
Astegolimab (IL33-IN). ELISA was used to detect the concentrations of mouse bone marrow-derived ribonuclease (BMDN) and elastase in HL-60 cell supernatant.
Astegolimab purchased from MedChemExpress. Usage Cited in: Cell Oncol (Dordr). 2025 Apr;48(2):487-504. [Abstract]
Astegolimab (IL33-IN). Western blot analysis of molecules associated with NET formation in mouse bone marrow-derived macrophages (BMDN).
-
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Steven G Kelsen, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790-798. [Content Brief]
[2]. Yi N, et al. Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. Cell Oncol (Dordr). 2025 Apr;48(2):487-504. [Content Brief]
[3]. Wu L, et al. Mechanistic role of RND3-regulated IL33/ST2 signaling on cardiomyocyte senescence. Life Sci. 2024 Jul 1;348:122701. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz